Who We Are: The boldest community fueling the best science and making the biggest impact in the fight against breast cancer.
Our History: In 1980, Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement.
Our Promise: To save lives and end breast cancer forever.
Our Motivation: Every 74 seconds, somewhere in the world, someone dies from
Our Scope: We have a global headquarters in Dallas, Texas, 120 Affiliates in the United States and three international Affiliates (Germany, Italy and Puerto Rico). We are active through partnerships in more than 30 countries around the world.
Funding: To date, we have invested more than $2.2 billion in research and life-saving community programs.
Research: Beginning with a single grant for $28,000 in 1982, we have now invested more than $750 million in research, making Komen the largest non-profit source of breast cancer research funding outside of the U.S. government. We currently manage more than 500 active research grants totaling nearly $300 million. Now that we have touched major breakthroughs in breast cancer science, Komen is focused on research to stem metastatic and aggressive disease, find scientifically sound preventive strategies, and investigate environmental links to breast cancer development.
Community Programs: Komen’s network of Affiliates annually funds nearly 2,000 community organizations providing education, screening, patient navigation and emergency financial support for those facing breast cancer in their communities. Komen has invested more than $1.3 billion in community grants since 1982.
Snapshot of Achievements:
Susan G. Komen for the Cure has changed how the world talks about and treats breast cancer (In 1982, people wouldn’t even say the words “breast cancer” aloud).
Komen grants have made major breakthroughs possible in breast cancer over the past 30 years.
Funding for discoveries in genetics and biology has evolved into personalized, less invasive treatments for what was once a “one-treatment-fits-all” disease.
Komen’s investments have helped drive down breast cancer mortality rates by 33 percent since 1991. The five year relative survival rate for early stage breast cancer (cancer that has not spread beyond the breast) is now 99 percent compared to 74 percent in 1982.
Komen is the only breast cancer organization attacking the disease on all fronts: in research, community outreach, education, advocacy and global work.